July, 2022: NeuroGT was awarded a two-year Phase I STTR grant from the NIH/NINDS ($702,684)

July, 2022: NeuroGT was awarded a two-year Phase I STTR grant from the NIH/NINDS ($702,684), supporting further development of NeuroGT’s gene therapy product (NGT-101) for treating Hurler syndrome (MPS I-H), towards clinical application and commercialization.